POMS

Name: POMS
Brand: POMS

Pharma First MES: Built for Science. Designed for People.

Est 1987|1 Ref Customers

LinkedIn 4K|Web traffic 1K|FTEs 49|HQ Redmond, Washington, US

01Competitive Landscape

Narrative analysis

1. Depth and market footprint - Körber PAS-X and Siemens Opcenter have broad marketed footprints in pharma. - POMS reports a long tenure in pharma MES with vendor-stated install counts but demonstrates less public third-party review volume. 2. Implementation model and relative complexity - POMS emphasizes off-the-shelf configurability and limited customization in vendor communications. - Larger suite vendors can offer deeper integration into broader enterprise stacks, but may require more extensive template governance and services. 3. Pricing and procurement - All three vendors typically use enterprise quoting for pricing. POMS describes simplified licensing; buyers should validate licensing models during procurement. 4. Analyst and independent signals - Third-party analyst placements and public analyst research are typically summarized by vendors; Körber has frequently referenced industry analyst placements in marketing materials.

	POMS (POMSnet Aquila)	Siemens (Opcenter Execution Pharma)	Körber (Werum PAS-X MES)
Starting Price	Not publicly listed (quote-based)	Generally quote-based; marketplace examples exist showing annualized pricing constructs for small user packs	Not publicly listed (quote-based)
Best For	GMP life sciences manufacturers prioritizing an operator-oriented MES, off-the-shelf configurability, and review-by-exception functionality	Enterprises seeking broad Siemens ecosystem integration and a suite-based pharma MES offering	Pharma/biotech/cell & gene manufacturers seeking a widely deployed pharma MES suite with a large global footprint
Key Strength	Vendor-stated strengths: focus on pharmaceutical manufacturing, vendor-described simplified licensing, inclusion of multiple modules by default, and availability of support services	Large vendor ecosystem and broad adoption across manufacturing software portfolios	Large install base and frequent placement in industry analyst evaluations for MES; strong pharma-specific feature depth
Key Weakness	Limited public third-party review volume and limited publicly documented security attestations	Potential for greater complexity and higher services cost for large-suite deployments	Potentially higher cost and heavier governance for suite-wide rollouts

01Competitive Landscape

Narrative analysis

Depth and market footprint
- Körber PAS-X and Siemens Opcenter have broad marketed footprints in pharma.
- POMS reports a long tenure in pharma MES with vendor-stated install counts but demonstrates less public third-party review volume.
Implementation model and relative complexity
- POMS emphasizes off-the-shelf configurability and limited customization in vendor communications.
- Larger suite vendors can offer deeper integration into broader enterprise stacks, but may require more extensive template governance and services.
Pricing and procurement
- All three vendors typically use enterprise quoting for pricing. POMS describes simplified licensing; buyers should validate licensing models during procurement.
Analyst and independent signals
- Third-party analyst placements and public analyst research are typically summarized by vendors; Körber has frequently referenced industry analyst placements in marketing materials.

	POMS (POMSnet Aquila)	Siemens (Opcenter Execution Pharma)	Körber (Werum PAS-X MES)
Starting Price	Not publicly listed (quote-based)	Generally quote-based; marketplace examples exist showing annualized pricing constructs for small user packs	Not publicly listed (quote-based)
Best For	GMP life sciences manufacturers prioritizing an operator-oriented MES, off-the-shelf configurability, and review-by-exception functionality	Enterprises seeking broad Siemens ecosystem integration and a suite-based pharma MES offering	Pharma/biotech/cell & gene manufacturers seeking a widely deployed pharma MES suite with a large global footprint
Key Strength	Vendor-stated strengths: focus on pharmaceutical manufacturing, vendor-described simplified licensing, inclusion of multiple modules by default, and availability of support services	Large vendor ecosystem and broad adoption across manufacturing software portfolios	Large install base and frequent placement in industry analyst evaluations for MES; strong pharma-specific feature depth
Key Weakness	Limited public third-party review volume and limited publicly documented security attestations	Potential for greater complexity and higher services cost for large-suite deployments	Potentially higher cost and heavier governance for suite-wide rollouts

POMS

01Competitive Landscape

Narrative analysis

02Market Map

01Competitive Landscape

Narrative analysis

02Market Map